Fig. 2.
FGF1ΔHBS prevents cardiac dysfunction and remodeling in db/db mice. a–e db/db mice were treated with FGF1ΔHBS (0.5 mg/kg body weight) or vehicle every other day for 16 weeks, and littermate db/m mice served as controls. a Echocardiographic parameters. n = 6. b Representative images of hematoxylin-eosin (H&E), WGA, Masson’s trichrome, Sirius red staining in cardiac tissues. c Quantification of myocyte area and cardiac fibrosis area in WGA, Masson’s trichrome and Sirius Red staining. n = 6. d Western blot analysis of collagen I (COL 1), collagen III (COL 3), myosin heavy chain (MyHC), cleaved caspase 3 (c-caspase 3) and transforming growth factor β1 (TGF-β1) in cardiac tissues; GAPDH was a loading control. e Densitometric quantification of western blots shown in d. n = 6. Data were mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001 in a, c; ***P < 0.001 vs. db/m, ###P < 0.001 vs. db/db in e